

Appendix

Table 1: An overview of the 12-month progression-free survival outcomes in patients with or without brain metastases

	Lorlatinib	Crizotinib
Patients with brain metastases	78%	22%
Patients without brain metastases	78%	45%

Table 2: An overview of the 12-month cumulative incidence of central nervous system progression in patients with or without brain metastases

	Lorlatinib	Crizotinib
Patients with brain metastases	7%	72%
Patients without brain metastases	1%	18%